All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked: What factors influence the adoption rates of novel multiple myeloma (MM) therapies in Latin America?
What factors influence the adoption rates of novel MM therapies in Latin America?
In this video interview, Vania Hungria provides an overview of the MM landscape in Latin America, focusing on the differences in access and adoption of novel therapies in public and private health care facilities. Hungria discusses the distribution of treatment between public and private institutions and the outcomes associated with treatment in each type of center.
The IMWG Revised International Staging System for multiple myeloma: Proposed second revision
The addition of chromosome 1q anomalies to the R-ISS criteria for NDMM has been shown to improve their prognostic power in terms of PFS and OS and may...
Novel risk score for predicting early relapse in patients with multiple myeloma
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure...
Subscribe to get the best content related to multiple myeloma delivered to your inbox